From The Economic Times · Rica Bhattacharyya and Vikas Dandekar · · 1m 20s
Bayer Targets GLP-1 Side Effect Solutions for India
Bayer plans to launch products addressing GLP-1 drug side effects in India by 2030.
In brief
Bayer plans to launch products addressing GLP-1 drug side effects in India by 2030. Bayer AG will assess digestive health, nutrition, and multivitamin products to counter GLP-1 obesity drug side effects in India. Originally reported by The Economic Times.
Bayer assesses GLP-1 side effect solutions
Bayer AG is exploring products to address constipation, nausea and muscle loss from GLP-1 obesity drugs in India.
“Bayer AG is assessing opportunities to bring products addressing side effects associated with glucagon-like peptide-1 (GLP-1) obesity drugs to India”
Bayer aims to triple India consumer health business
Bayer plans to triple its consumer health revenue in India by 2030, targeting it as its third-largest global market.
“We should be able to triple the India business in terms of the revenue between now and 2030”
GLP-1 drugs cause significant side effects
GLP-1 obesity drugs cause constipation, nausea and muscle loss requiring counter products in the US market.
“The GLP-1s have brought in a seismic sort of innovation into the market”
Bayer evaluates digestive health products
Bayer identifies digestive health as a key growth area in India with significant gut health challenges.
“We also have a lot of new entrants in our space. We're competing not just with global players but also with local players”
Bayer will launch counter products in India
Bayer will assess and launch digestive health, nutrition and multivitamin products for GLP-1 side effects in India.
“Yes. The team is doing an assessment. We will support the team to bring whatever products they want to bring to India”
Bayer avoids distribution partnerships in India
Bayer plans to build its own distribution network in India rather than partner with local distributors.
“We would run the business ourselves, so we're building our own distribution - and so we would not look for a distributing partner”
Bayer targets affordable product access in India
Bayer aims to make its products accessible to low-income households through pricing and presentation strategies.
“We don't want our products to only be for rich countries that can buy expensive vitamins”
What matters most
Bayer AG will assess digestive health, nutrition, and multivitamin products to counter GLP-1 obesity drug side effects in India.
